Viral Vector Production in HEK Cells

Introduction

HEK293, a human embryonic kidney cell line, has been widely used for the production of recombinant proteins and viral vectors, including adenoviral vectors. HEK293 cells have several advantages for viral vector production, such as high transfection efficiency, high cell growth rate, and the ability to support the replication of adenoviral vectors.

CD Biosynsis has extensive experience in viral vector production in HEK cells, utilizing our advanced technology and expertise to provide high-quality services for our clients.

Figure 1: Viral vector synthesis network. (Nguyen Tam N. T., et al. 2021)

Our Services for Viral Vector Production in HEK Cells

 Vector Design and Construction

We can engineer different types of viral vectors, such as adenoviral vectors, lentiviral vectors, and AAV vectors, to meet your research or therapeutic needs. Our vector design and construction services include:

• Selection of the most appropriate viral vector type for your application
• Design and engineering of viral vectors for gene therapy, vaccine development, or research purposes
• Optimization of vector expression levels and transduction efficiency
• Incorporation of specific promoters, enhancers, or other regulatory elements to achieve the desired expression profile
• Cloning of the vector into a suitable plasmid or viral backbone
• Verification of the vector sequence and functionality before proceeding to the next step

HEK Cell Culture and Transfection

Our HEK cell culture and transfection services include:

• Seed culture and expansion of HEK293 cells
• Optimization of transfection conditions for maximum transfection efficiency and minimal cytotoxicity
• Transfection of HEK293 cells with the engineered viral vector
• Monitoring of cell growth and vector expression levels
• Harvesting of the viral vector from HEK293 cells

Viral Vector Production and Purification

Once the viral vector is produced in HEK293 cells, we can purify it using our optimized protocols and state-of-the-art equipment. Our viral vector production and purification services include:

• Large-scale production of viral vectors for preclinical and clinical applications
• Optimization of virus production conditions to maximize yield and purity
• Purification of viral vectors using chromatography or ultracentrifugation
• Removal of impurities, such as host cell proteins, DNA, or endotoxins, using appropriate methods
• Quality control testing of purified viral vectors to ensure purity, potency, and safety

Quality Control and Analysis

Our quality control and analysis services include:

• Endotoxin testing to ensure the absence of bacterial contamination
• Sterility testing to ensure the absence of fungal or microbial contamination
• Potency assays to determine the biological activity of the viral vector
• Verification of the vector sequence and functionality
• Characterization of the viral vector using techniques such as gel electrophoresis, Western blotting, or PCR

Our Advantages

• Advanced Technology
• Experienced Team
• Flexibility

  We offer flexible options for viral vector production, from small-scale research to large-scale manufacturing.

• Regulatory Compliance

  We adhere to strict regulatory guidelines for viral vector production and purification, ensuring compliance with the highest standards of safety and quality.

CD Biosynsisoffers services for viral vector production in HEK cells include vector design and construction, HEK cell culture and transfection, viral vector production and purification, and quality control and analysis. We have extensive experience in viral vector production and can provide customized solutions to meet your specific needs. We utilize the latest technology and equipment for viral vector production, ensuring high quality and consistency of our products. Contact us today to discuss your viral vector production needs and how we can help you achieve your research or therapeutic goals.

References

1. Van Der Loo Johannes C. M., Wright J. Fraser. Progress and challenges in viral vector manufacturing. Human Molecular Genetics, 2016, 25(R1): R42-R52.
2. Petiot E., et al. Influence of HEK293 metabolism on the production of viral vectors and vaccine. Vaccine, 2015, 33(44): 5974-5981.
3. Nguyen Tam N. T., et al. Mechanistic model for production of recombinant adeno-associated virus via triple transfection of HEK293 cells. Molecular Therapy - Methods & Clinical Development, 2021, 21: 642-655.

Please note that all services are for research use only. Not intended for any clinical use.